Experimental Treatment for NF-1 Gets Orphan Drug Designation
frolicsomepl / Pixabay

Experimental Treatment for NF-1 Gets Orphan Drug Designation

According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics recently announced that the US Food and Drug Administration (FDA) has given the company's experimental product PD-0325901 Orphan Drug…

Continue Reading Experimental Treatment for NF-1 Gets Orphan Drug Designation
A New Drug Application Has Been Submitted For a Potential Vascular Ehlers-Danlos Syndrome Treatment
DarkoStojanovic / Pixabay

A New Drug Application Has Been Submitted For a Potential Vascular Ehlers-Danlos Syndrome Treatment

Acer Therapeutics has submitted a New Drug Application to the United States Food and Drug Administration on behalf of Edsivo™, their experimental treatment for vascular Ehlers-Danlos syndrome. To find out…

Continue Reading A New Drug Application Has Been Submitted For a Potential Vascular Ehlers-Danlos Syndrome Treatment

Start-Up Develops AI Tech to Find Treatments for Rare Diseases; Wants to Help 100 Diseases by 2025

Forbes reports that Healx, a British biotech startup, is using the power of artificial intelligence to find new uses for existing drugs that treat rare diseases. "Healx combines AI technology, pharmacology…

Continue Reading Start-Up Develops AI Tech to Find Treatments for Rare Diseases; Wants to Help 100 Diseases by 2025

Goethe University Has Been Awarded Over One Million Euros to Investigate How to Standardise Clinical Data, Helping Rare Disease Patients

Goethe University in Frankfurt, Germany has been awarded a grant of more than one million euros as part of a large-scale project in Europe to standardise and make available clinical…

Continue Reading Goethe University Has Been Awarded Over One Million Euros to Investigate How to Standardise Clinical Data, Helping Rare Disease Patients
Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment
chezbeate / Pixabay

Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment

According to a story from epidermolysisbullosanews.com, the biotechnology company TWi Biotechnology, Inc., recently announced that is has begun enrollment for its Phase 2 trial. This trial will test the company's…

Continue Reading Phase 2 Trial for an Experimental Epidermolysis Bullosa Treatment Begins Enrollment